NuCana Shares Plummet as Another Chemotherapy Replacement Fails Phase II
NuCana’s chemotherapy replacement has failed to improve progression-free survival in a Phase II test, sending the biotech’s shares down by 50%.
NuCana Shares Plummet as Another Chemotherapy Replacement Fails Phase II Read More »
